HBsAg Profiles in Patients Receiving Peginterferon Alfa‐2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses
The Journal of Infectious Diseases2010Vol. 202(1), pp. 86–92
Citations Over TimeTop 10% of 2010 papers
Ming‐Lung Yu, Chuan‐Mo Lee, Wan‐Long Chuang, Sheng‐Nan Lu, Chia‐Yen Dai, Jee‐Fu Huang, Zu‐Yau Lin, Tsung‐Hui Hu, Chien‐Hung Chen, Chao‐Hung Hung, Jin‐Houng Wang, Chi‐Ling Chen, Jia‐Horng Kao, Ming–Yang Lai, Chen‐Hua Liu, Tung‐Hung Su, Shun‐Sheng Wu, Li‐Ying Liao, Hsing‐Tao Kuo, You‐Chen Chao, Shui‐Yi Tung, Sien‐Sing Yang, Pei‐Jer Chen, Chun‐Jen Liu, Ding‐Shinn Chen
Abstract
HBsAg quantification appears to be a useful indicator of posttreatment outcome in patients dually infected with HBV and hepatitis C virus.
Related Papers
- Efficacy of Conventional Interferon alpha–2 b plus Ribavirin combination in the treatment of chronic Hepatitis C naive patients -(2005)
- → Ribavirin with or without alpha interferon for chronic hepatitis C(2002)19 cited
- → PIN19 THE COST-EFFECTIVENESS ANALYSIS OF COMBINATION OF PEGINTERFERON ALFA-2A AND RIBAVIRIN VERSUS COMBINATION OF PEGINTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C IN POLAND(2004)1 cited
- → Alpha-interferon with ribavirin for the treatment of chronic hepatitis C in treatment naive patients(2000)2 cited
- → PIN8 COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON (ALFA-2B) WITH RIBAVIRIN COMPARED WITH PEGINTERFERON (ALFA-2A) WITH RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C(2010)